Expert Analysis

Clinical Updates in HCV Treatment

Source: CCO Independent Conference Coverage of the 2007 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Clinical Updates in HCV Treatment

Faculty:

Peter Ferenci, MD
Ira M. Jacobson, MD
Karen L. Lindsay, MD, MMM

CME CREDIT INFORMATION

Release Date: 06/27/07

Expiration Date: 06/26/08

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing CE credits

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe data regarding the safety and efficacy of novel therapies for HCV in treatment-naive and treatment-experienced patients
Specify the latest data available on efficacy and durability of currently available HCV therapies
Review recent studies of methods for monitoring and individualizing HCV therapy

Topics covered include:

Telaprevir Plus Peginterferon alfa-2a and Ribavirin in HCV Genotype 1
Valopicitabine Plus Peginterferon alfa-2a in Treatment-Naive Patients
HCV-796 Plus Peginterferon alfa-2b in Treatment-Naive Patients
Albinterferon vs Peginterferon Alfa-2a in Interferon-Naive Patients With HCV Genotype 1
Albinterferon in Interferon-Naive Patients With HCV Genotype 2/3
Novel HCV Agents in Early Development: BILB 1941, ACH-806, DEBIO-025
Taribavirin Plus Peginterferon alfa-2a vs Ribavirin Plus Peginterferon alfa-2a in Treatment-Naive Patients
5-Year Follow-up of Response Durability With Peginterferon alfa-2a With or Without Ribavirin
Dosage and Other Characteristics of Ribavirin as Predictors of SVR
Individualized Duration of Therapy Based on Time to First Undetectable HCV RNA

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.